Idenix raises $107M for hep C R&D, litigation; Alimera private placement adds $37.5M;

@FierceBiotech: Neurotrope hires 3: a CMO and heads of commercial ops & regulatory affairs. Release | Follow @FierceBiotech

@JohnCFierce: AstraZeneca adds a combo research pact to a flurry of new antibiotics deals. Coverage | Follow @JohnCFierce

@DamianFierce: Pfizer's R&D spend is $2.5B smaller than it was in 2011, but does smaller = more efficient? Story | Follow @DamianFierce

@EmilyMFierce: At least 103 million cases of childhood disease have been prevented by vaccines since 1924, new survey says. Blog post via Science News | Follow @EmilyMFierce

> Idenix Pharma's ($IDIX) CEO tells TheStreet's Adam Feuerstein about his plans for the $107 million the biotech just raised. In addition to continuing its quest for new hepatitis C drugs, despite the rapid progress of leaders like Gilead ($GILD) and AbbVie ($ABBV), Idenix also plans to follow up on its patent litigation with Gilead. Story

> Alimera Sciences ($ALIM) has raised $37.5 million from a private placement. The money will be used to back its research on ophthalmic pharmaceuticals. Release

Medical Device News

@FierceMedDev: Federal judge clears path for failure-to-warn claims against St. Jude. Article | Follow @FierceMedDev

@MichaelGFierce: Artificial pancreas news: U.K. researchers unveil device, J&J snags Can. approval of closed-loop system. News | Follow @MichaelGFierce

@EmilyWFierce: Covidien gets Japanese stamp of approval for Tri-Staple technology. More | Follow @EmilyWFierce

@GalenMoore: Judge green-lights 5 lawsuits claiming St. Jude Medical failed to warn about Riata problems. Report  | Follow @GalenMoore

> Despite Medtronic's failure, ReCor sticks to its guns on hypertension. News

> Low-cost ventilator maker OneBreath pulls in $3M to expand in emerging markets. Item

> Shakeup at St. Jude: Cardio pres. Frank Callaghan to retire as units merge. More

Pharma News

@FiercePharma: Endo Pharma is No. 10 on our list of 2013's largest pharma layoffs. Special Report | Follow @FiercePharma

@TracyStaton: Lilly announced 1,000 job cuts in 2013. 2014 is expected to be even bleaker. Report | Follow @TracyStaton

@EricPFierce: Pharma keeps whacking jobs, but not always because of the patent cliff. Report | Follow @EricPFierce

@CarlyHFierce: NICE consults again on decision to recommend new prostate cancer drug Xtandi from Astellas. Release | Follow @CarlyHFierce

> AstraZeneca joins stepped-up antibiotic R&D action with FOB Synthesis deal. Item

> Report: FDA allowed 'high risk' animal antibiotics to remain in use on U.S. farms. Story

> GSK warns of a possible global shortage of chickenpox vaccines. More

Pharma Manufacturing News

> India has different attitudes about the standards at facilities targeted by the FDA. Story

> Actavis is selling a China plant as it unloads manufacturing capacity globally. Article

> Ranbaxy's repeat violation elicits swift FDA action. Piece

> GSK blames chickenpox vaccine shortage on plant problems. More

> Feds nab two men from Turkey in effort to counter counterfeits. News

> NextSource brings back Lomustine, the brain cancer drug that BMS stopped making. Item

Biotech Research News

> Genetic platform allows scientists to tap marine microbiota for drug discovery. Story

> Discovery links genes to excess belly fat. More

> Plant-based compound maintains memory against Alzheimer's in mice. Piece

> Researchers repair retinas in mice with virus-free stem cells. News

> Reengineered antibiotic gains ability to thwart drug-resistant TB strains. Article

> $3M initiative will focus on finding new drugs for Alzheimer's. Item

Suggested Articles

Orum Therapeutics raised $30 million to expand the applications for for its cell-penetrating antibody technology.

Genentech followed a $1 billion pact with Sosei Heptares with discovery deals around cancer and neurological diseases with Skyhawk and Convelo.

The partners will use wearable devices to assess how heart failure patients function and feel after being discharged from hospitals.